Q-restrain Therapy:
Immune Support Therapy
Utilizing specialized gene sequences to disrupt cell replication
Article Review & Sharing
Information of Q-restrain Therapy in Hong Kong! What is Q-restrain Therapy - Supportive
Oligonucleotide Therapy?
Our Therapies
Q-REstrain Therapy
Q-REstrain is a breakthrough in personalized, autologous therapy for cancer—a sophisticated non-manipulated, personalized therapy that targets the specific genetic sequences driving a patient’s cancer, viral infections, or Lyme disease and inhibits expression of those genetic sequences. This innovative personalized, autologous therapy goes beyond traditional approaches by creating a uniquely tailored treatment designed specifically for individual needs.
What is Q-REstrain?
Advanced microRNA for Cancer, Viruses & Lyme
Autologous Therapy
Q-REstrain is completely personalized to the patient. Using a simple blood sample, our laboratory scientists analyze the patient’s specific genetic markers to create a therapy that targets only the desired genes.
Gene Silencing
Q-REstrain utilizes advanced RNA technology to “silence” problematic genetic sequences. This advanced therapy in cancer uses small oligonucleotide molecules that are complementary to specific gene sequences, effectively turning off the signals that allow certain cancers, viruses, or Lyme disease to thrive through precise gene silencing technology. By blocking specific messenger RNA (mRNA) sequences, Q-REstrain prevents proteins essential for cell survival or metabolism from being produced in your body.
How Does Q-REstrain Work?
Q-REstrain takes advantage of oligonucleotide molecules – microRNAs isolated by the patient’s sample. The Q-REstrain molecule has a potent ability to block specific mRNA with a very high rate of specificity; therefore expression of only the desired gene is inhibited.
5-Step Process
Certified RGCC practitioners receive training and support through RGCC college and the RGCC practitioner network.
Step 1: Consultation
Patient connects with a trained RGCC practitioner who evaluates their case and determines if Q-REstrain is a good fit.
Step 2: Pre-Testing
Patient completes required diagnostic tests (Oncotrace for cancer or serum lab work for virus/Lyme).
Step 3: Blood Collection
Patient provides blood sample for personalized therapy development.
Step 4: Therapy Production
Customized Q-REstrain therapy is created in our state-of-the-art laboratory (14 working days).
Step 5: Treatment
Patient receives personalized therapy through an RGCC practitioner.
Who is Q-REstrain For?
Q-REstrain therapy offers hope and healing for patients facing multiple challenging conditions:
Cancers
Solid Tumors: Effective for most solid tumor types across various stages Hematologic Malignancies: Blood cancers including leukemias, lymphomas, and myelomas
Note: CNS (central nervous system) cancers are not suitable for Q-REstrain therapy
Viruses
Q-REstrain successfully targets a comprehensive range of viral infections, such as:
Herpes Viruses: HSV1/HSV2, HHV6, Varicella Zoster (shingles), Epstein-Barr Virus (EBV), Cytomegalovirus (CMV)
Human Papilloma Virus: HPV-16/18 and HPV-6/11
Hepatitis: Hepatitis B and C viruses
Other Viruses: Coxsackie Virus, HIV, HTLV1
Lyme Disease
Targeted treatment for Lyme disease and associated co-infections, helping patients overcome these complex, chronic conditions.
Therapy Details
Is Q-REstrain Safe?
Q-REstrain therapy has been extensively studied with thousands of research studies confirming its safety profile. The therapy is well-tolerated by most patients, with a strong track record of successful outcomes across diverse patient populations.
Sample of Studies:
Safety of antisense oligonucleotide and siRNA-based therapeutics
Antisense oligonucleotides as therapeutic agents
In vivo and in vitro studies of antisense oligonucleotides – a review
Therapeutic Antisense Oligonucleotides Are Coming of Age
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
The powerful world of antisense oligonucleotides: From bench to bedside
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Pre-therapy Requirements
- Positive RGCC test result confirming circulating tumor cells (CTCs)
- Test must be within 6 months
For Viral or Lyme Patients:
- Positive test confirming presence of targeted pathogen
- PCR or antibody results accepted
- Test must be within 6 months from a reputable laboratory
Treatment Schedule
Cancer: Maximum of 4 treatments per 12-month period, spaced a minimum of 3 months apart
Viral/Lyme: Maximum of 9 treatments per 12-month period, spaced a minimum of 7 days apart
Important:
- Q-REstrains work for a long time and can accumulate in the body and build up
- Multiple Q-REstrain treatments cannot be given on the same day
- No other therapies are allowed on the same day as a Q-Restrain administration
Mandatory Follow-Up Tests
- Cancer Patients: Oncotrace or Oncotrail RGCC tests every 3-4 months to monitor CTC status and treatment effectiveness
- Viral/Lyme Patients: Follow-up testing 4-6 months post-treatment using the same laboratory that ordered the original Q-REstrain
Possible Adverse Reactions
While generally well-tolerated, some patients may experience:
- Mild headaches
- Temporary increased fatigue
- Flu-like symptoms
- Cancer patients: Possible pain at surgical sites, risk of Tumor Lysis Syndrome with large tumors
- Viral/Lyme patients: Herxheimer-type reactions, potential co-infection flares
Contraindications & Considerations
Absolute Contraindications:
- Pregnancy or breastfeeding
- Recent blood transfusion
- Recent chemotherapy or radiotherapy (must wait 21 days)
- Radioactive seed therapy (permanent contraindication for cancer)
- Delta T-Cell therapy (permanent contraindication for cancer)
Age Restrictions:
- Cancer treatment: Children under 12
- Viral/Lyme treatment: Children under 5
Special Considerations
Patients with large tumor burden require careful evaluation for Tumor Lysis Syndrome risk before treatment.
Patients should consult with their RGCC Practitioner about other potential contraindications.
Cutting-Edge Science
Explore scientific papers and articles regarding antisense oligonucleotide therapy.
Clinical Outcomes
Q-REstrain therapy demonstrates remarkable success rates across different conditions:
- Cancer Patients: 78% positive clinical outcome (complete response, partial response, or stable disease)
- Virus-Infected Patients: 91% positive clinical outcome
- Lyme Disease Patients: 95% positive clinical outcome
Clinical outcomes are defined as complete response, partial response, or disease stabilization. Individual results may vary, and success encompasses any positive response, from complete eradication to disease stabilization.
Why Choose Q-REstrain?
- Precision Personalization: Every Q-REstrain therapy is uniquely designed for your specific genetic profile—no one-size-fits-all approach to personalized therapy and cancer.
- Long-Lasting Action: A single treatment works continuously for up to six months, providing sustained therapeutic benefit through advanced gene silencing.
- Minimally Invasive: Requires only a simple blood draw for analysis and a single IV treatment for this targeted personalized therapy.
- Cutting-Edge Science: Utilizes the latest RNA interference technology backed by thousands of safety studies in cancer personalized therapy.
- Comprehensive Coverage: Effective against cancers, multiple viral infections, and Lyme disease.
- Proven Results: High success rates with excellent safety profile across diverse patient populations.
- Expert Support: Treatment guided by RGCC-trained practitioners with specialized expertise in personalized medicine.
Ready to Explore
Q-REstrain Therapy?
Take control of your health journey with personalized gene silencing therapy.
Q-REstrain offers hope through precision personalized therapy for cancer—targeting the specific genetic drivers of your condition while preserving your healthy cells. Our expert team is ready to guide you through this innovative autologous, personalized therapy treatment option.
Transform your treatment approach with the power of personalized medicine.
Contact us now to discuss whether Q-REstrain therapy is right for you.